<?xml version="1.0" encoding="UTF-8"?>
<p>WHO’s Strategic Advisory Group of Experts (SAGE) on Immunization met in October 2018 in Geneva to discuss the development of candidate Ebola vaccines and the progress made in implementing the “expanded access and compassionate use” vaccine protocol in the DRC, but no recommendation for immunizing pregnant women was made. At this meeting, SAGE reviewed the available data for rVSV-ZEBOV based upon clinical outcomes from those women who had been inadvertently vaccinated in early pregnancy or women who became pregnant shortly after being immunized [
 <xref rid="B75-vaccines-08-00038" ref-type="bibr">75</xref>,
 <xref rid="B76-vaccines-08-00038" ref-type="bibr">76</xref>]. SAGE conceded that significant data gaps existed, and that there was loss to follow-up and a lack of an appropriate control group in most instances. Within these constraints, the investigators did not detect any statistically significant increase in the risk of pregnancy loss associated with periconception or perinatal vaccination, but neither could they exclude it. Given the gaps in data, SAGE did not believe that enough information existed at the time to issue a definitive recommendation on whether pregnant women should be offered the vaccine, and thus deferred to local authorities in the DRC to determine the ongoing strategy [
 <xref rid="B39-vaccines-08-00038" ref-type="bibr">39</xref>]. They stated:
</p>
